Clinical Trial Search

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Biochemical Control Rate — 71; 0 Participants

Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants

Primary: Safety - Evaluate the Frequency of Treatment Related Adverse Events — 30 Participants

Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants

Primary: Number of Device and Procedure Related Adverse Events — 24 Number of Adverse Events

Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants

Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants

Primary: Acute Grade 3 (NCI CTC v4.0) or Higher Treatment-related Toxicity Rate. — 0; 0 Participants

Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants

Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants

Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: All Cause Mortality — 171; 183 Participants

Primary: Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment — 26 Participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190

Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants

Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants

Primary: Prostate Biopsy — 0; 3; 8; 11 participants

Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives

Primary: The Area of the Transperineal Targeted Microwave Ablation (TMA) Induced Tissue Death Assessed by Triphenyltetrazolium Chloride (TTC) Staining

Primary: Incidence of Grade 3+ Gastrointestinal Toxicity — 0 participants

Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…

Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants

Primary: Safety, as Measured by the Number of Patients With at Least One Adverse Event as Assess by NCI Common Terminology Criteria for Adverse Events (CTCAE) vs. 40 When…